
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2021.

Commission File Number: **001-40065**

IM Cannabis Corp.

(Exact Name of Registrant as Specified in Charter)

Kibbutz Gllil Yam, Central District, Israel 4690500

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IM CANNABIS CORP.
(Registrant)

Date: April 12, 2021

By: */s/ Oren Shuster*

Name: Oren Shuster

Title: Chief Executive Officer and Director

EXHIBIT INDEX

<u>99.1</u>	<u>Form 9 - Notice of Issuance or Proposed Issuance of Listed Securities dated April 1, 2021</u>
<u>99.2</u>	<u>Form 7 - Monthly Progress Report dated April 9, 2021</u>
<u>99.3</u>	<u>Press Release dated April 12, 2021</u>

FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities¹)

Name of Listed Issuer:

Symbol(s):

IM Cannabis Corp. (the "Issuer")	IMCC
----------------------------------	------

Date: April 1, 2021 Is this an updating or amending Notice: Yes No

If yes provide date(s) of prior Notices: _____.

Issued and Outstanding Securities of Issuer Prior to Issuance: 50,498,009.

Pricing

Date of news release announcing proposed issuance: April 1, 2021 or

Date of confidential request for price protection:

Closing Market Price on Day Preceding the news release:

\$8.86 or Day preceding request for price protection:

Closing

Number of securities to be issued: To be determined based on closing prices on acquisition¹

Issued and outstanding securities following issuance: To be determined based on closing prices on acquisition²

Instructions:

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A - Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B - Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.

¹The number of securities to be issued shall be determined in accordance with the Arrangement Agreement (as defined herein) will be based on the number of issued and outstanding securities immediately prior to the closing of the Transaction. An amended Form 9 shall be submitted forthwith upon closing.

²The number of issued and outstanding securities following the issuance will be determined immediately prior to the closing of the Transaction. An amended Form 9 shall be submitted forthwith upon closing.

5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 - Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 - Distributions*. In addition, the completed form must be delivered to listings@thecse.com with an appendix that includes the information in Table 1B for ALL places.

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

September 2018

Page 2

Part 1. Private Placement

Table 1A - Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Cayman Islands	1		<u>To be determined base on closing date. Approximately \$5.4 million</u>
Total number of purchasers:	1		
Total dollar value of distribution in all jurisdictions: ³			

Table 1B - Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date ⁽¹⁾	Describe relationship to Issuer ⁽²⁾
1909203 Ontario Inc., a company registered under the laws of the Cayman Islands	TBD number of common shares 155,340 common share purchase warrants	Lower of 15% discount to signing or closing price	N/A	Accredited Investor	14,214,286	Closing Date of MYM Acquisition (see details below)	Lender; Holding company of Director/ CEO of Issuer.

³ To be determined based on closing date. Approximately \$5.4 million

An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: Approximately \$5.4m⁴.
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. Repayment in full of loan, including accrued and unpaid interest
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: All shares to be paid to holding company of director/CEO of issuer to repay loan.
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities. Forgiveness of secured loan of lender previously disclosed on issuer's SEDAR profile.
5. Description of securities to be issued:
 - (a) Class Common Shares.
 - (b) Number TBD.
 - (c) Price per security Lower of 15% discount to signing or closing price.
 - (d) Voting rights One share one vote.
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
 - (a) Number 155,340.
 - (b) Number of securities eligible to be purchased on exercise of warrants (or options) 155,340 common shares.
 - (c) Exercise price 120% of lower of signing and closing price _____.

⁴ Shall be determined on the closing date of the Transaction. An amended Form 9 shall be submitted forthwith upon closing.

- (d) Expiry date three years from date of issuance.
7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount N/A.
- (b) Maturity date N/A.
- (c) Interest rate N/A.
- (d) Conversion terms N/A.
- (e) Default provisions N/A.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- Not applicable
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): N/A.
- (b) Cash N/A.
- (c) Securities N/A.
- (d) Other N/A.
- (e) Expiry date of any options, warrants etc. N/A.
- (f) Exercise price of any options, warrants etc. N/A.
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship.
- N/A.
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).
- N/A.
11. State whether the private placement will result in a change of control.

No, but issued in connection with change of control of MYM.

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. Shares issued in connection with arrangement pursuant to which all MYM shares will be purchased by IM Cannabis Corp.
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

September 2018

Page 6

Part 2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: All issued and outstanding shares of MYM Nutraceuticals Inc. ("MYM"). MYM owns two licensed producers, Highland Grow Inc. and Sublime Culture Inc., which are licensed producers under the Cannabis Act (Canada). IMC is acquiring MYM for shares of IMC based on a fixed exchange ratio of 0.022 IMC shares for each MYM share. The transaction is subject to customary conditions to closing and is expected to close in H2 2021.
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: Proposed acquisition pursuant to an arrangement agreement dated April 1, 2021 ("Arrangement Agreement"). Prior to the acquisition MYM is unrelated to the issuer. Shares in the issuer will be issued as consideration for the shares in MYM pursuant to the Arrangement Agreement.
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
 - (a) Total aggregate consideration in Canadian dollars: TBD - Exchange ratio for shares.
 - (b) Cash: N/A.
 - (c) Securities (including options, warrants etc.) and dollar value: each MYM share, including shares issued on acceleration of in the money options and warrants, to be purchased for 0.022 common shares of IMC
 - (d) Other: N/A.
 - (e) Expiry date of options, warrants, etc. if any: N/A.
 - (f) Exercise price of options, warrants, etc. if any: N/A.
 - (g) Work commitments: N/A.
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

Arm's length negotiation. MYM formed an independent committee. Both MYM and IMC obtained fairness opinions.

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: N/A

6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

NOTE: All shareholders of MYM to receive IMC common shares based on the exchange ratio.

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDNS)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: Target is a CSE traded company.

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): N/A.

- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): N/A.
- (b) Cash N/A.
- (c) Securities N/A.
- (d) Other N/A.
- (e) Expiry date of any options, warrants etc. N/A.
- (f) Exercise price of any options, warrants etc. N/A.

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. N/A.
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. N/A.
- .

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

September 2018

Page 9

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated April 5, 2021.

Oren Shuster
Name of Director or Senior Officer

"Oren Shuster"
Signature

Chief Executive Officer
Official Capacity

Appendix A

PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, "CSE or the "Exchange") collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange's obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street - 9th Floor, Toronto, ON, M5J 2W4.

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC").

Trading Symbol: IMCC

Number of Outstanding Listed Securities as of 31/03/2021:

50,498,009 Common Shares, 9,289,038 Warrants

Date: April 9, 2021

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
 - **On March 1, 2021, the Issuer's Common Shares commenced trading on the Nasdaq Capital Market ("NASDAQ") under the ticker symbol "IMCC".**
 - **On March 8, 2021, the Issuer announced that Focus Medical Herbs Ltd. ("Focus Medical") signed a multi-year supply agreement with GTEC Holdings Ltd. ("GTEC"), a Canadian licensed producer of handcrafted and high quality cannabis (the "GTEC Agreement"). According to the GTEC Agreement, Focus Medical will import GTEC's high-THC medical cannabis flower into Israel to be sold under the IMC brand. With the arrival of these commercial shipments, the Issuer will launch a new category of imported premium indoor medical cannabis products. The import of the Canadian-grown high-THC strains from GTEC's subsidiary, Grey Bruce Farms Incorporated ("GBF"), is expected to commence in Q2 2021, subject to fulfilling all regulatory requirements in relation to such import, including compliance with the Israeli Ministry of Health regulations and receipt of a valid export license from Health Canada. According to the GTEC Agreement, Focus Medical will purchase a minimum quantity of 500 kg of high-THC medical cannabis flower from GBF and will be the exclusive recipient of GTEC cannabis products in the Israeli market for a period of 12 months from the date that the first shipment of GTEC products arrives in Israel and such exclusive term can be extended under the terms of the GTEC Agreement by an additional 6 months.**
 - **On March 12, 2021, the Issuer filed a preliminary short form base shelf prospectus (the "Preliminary Shelf Prospectus") with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada (the "Securities Commissions"), and on March 15, 2021, the Issuer filed a corresponding shelf registration statement on Form F-10, with the United States Securities and Exchange Commission ("SEC") under the Multijurisdictional Disclosure System established between Canada and the United States.**
-

- On March 18, 2021, the Issuer closed its acquisition of all of the issued and outstanding common shares of Trichome Financial Corp. ("Trichome"), previously announced on December 30, 2020, by way of a plan of arrangement under the *Business Corporations Act* (Ontario) (the "Trichome Transaction"). See Section 7 below for more information.
- On March 31, 2021, in connection with the Preliminary Shelf Prospectus, the Issuer filed a final short form base shelf prospectus (the "Final Shelf Prospectus") with the Securities Commissions and a corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the SEC. The Final Shelf Prospectus and the Registration Statement enables the Issuer to offer up to US\$250,000,000 (or its equivalent in other currencies) of common shares, warrants, subscription receipts, debt securities, units (collectively, the "Securities"), or any combination of such Securities from time to time, during the 25-month period that the Final Shelf Prospectus is effective. The specific terms of any offering under the Final Shelf Prospectus and the intended use of the net proceeds will be established in a prospectus supplement, which will be filed with the Securities Commissions and the SEC in connection with any such offering.

2. Provide a general overview and discussion of the activities of management.

Management of the Issuer ("Management") is focused on continuing the Issuer's growth in all three markets in which it currently operates: Israel, Germany and Canada. Following the Trichome Transaction, Management is focused on increasing the Issuer's presence in Canada by executing its merger & acquisition strategy and seeking to acquire additional licensed cannabis producers with the objective of becoming a dominant supplier in the premium and super premium segment of the Canadian recreational cannabis market, while also identifying new strategic investments and growth opportunities in Israel and Europe, including, but not limited to, securing additional supply and distribution agreements in Germany and the rest of Europe, and additional sales and supply agreements in Israel through Focus Medical.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

- **In March 2021, Adjupharm GmbH ("Adjupharm") launched a new medical cannabis flower product with THC/CBD levels of 17%/1%, under the IMC brand. The new product will be distributed pursuant to certain Adjupharm's distribution agreements with its German distribution partners.**
-

- **In March 2021, Adjupharm entered into several agreements for the purchase and resale of COVID-19 antigen test kits, as further described under Section 5.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

- **On March 5¹, 2021, Trichome's subsidiary, Trichome JWC Acquisition Corp ("TJAC") entered into a wholesale supply agreement (the "TJAC Supply Agreement") with a third-party, Canadian licensed producer called Peace Naturals Project Inc. ("Peace Naturals"), which is a subsidiary of Cronos Group Inc. Per the terms of the TJAC Supply Agreement, TJAC has agreed to provide a one-time shipment of approximately 150 kilograms of cannabis product to Peace Naturals. Neither Peace Naturals nor Cronos Group Inc. are related parties of the Issuer or any of its subsidiaries.**
- **On March 8, 2021, Focus Medical and GTEC signed the GTEC Agreement, as further detailed under Section 1 above. GTEC is not a Related Person of the Issuer.**
- **On March 12, 2021, Adjupharm entered into a supply agreement with Northern Green Canada Inc. ("NGC") (the "NGC Supply Agreement"). Under the terms of the NGC Supply Agreement, NGC will provide Adjupharm with three new strains of medical cannabis products, to be distributed under the IMC brand to German pharmacies pursuant to Adjupharm's distribution agreements with its German distribution partners. Shipments from NGC are expected to commence in Q2 2021. NGC is not a Related Person of the Issuer.**
- **On March 29, 2021, Adjupharm entered into a supply agreement with MediPharm Labs Corp. ("MediPharm Labs") for certain medical cannabis extract products to be delivered by MediPharm Labs over an initial two-year term with an automatic two-year extension period. MediPharm Labs is not a Related Person of the Issuer.**

¹The transaction with Trichome closed on March 18, 2021. As Trichome is no longer a reporting issuer, IMCC includes this information in its monthly report.

- **In March 2021, Adjupharm entered into two supply agreements with supply partners in China (the "Suppliers"), under which Adjupharm shall buy COVID-19 rapid antigen tests kits (the "Antigen Supply Agreements"). Concurrently, Adjupharm entered into several resale agreements with reseller partners in Germany (the "Resellers") (the "Reseller Agreements"), under which Adjupharm shall sell the COVID-19 antigen test kits purchased under the Antigen Supply Agreements, to be distributed to pharmacies and retailers in Germany. None of the Suppliers or Resellers are Related Persons of the Issuer.**
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
- **On March 30, 2021, Adjupharm and Zur Rose Pharma GmbH ("Zur Rose") reached a settlement to terminate their medical cannabis sales agreement that was announced by the Issuer on July 15, 2020.**
 - **On March 31, 2021, Trichome received repayment of its outstanding secured loan to Heritage Cannabis Holdings Corp. ("Heritage"). Trichome provided Heritage with a single advance of CDN \$4,875,000 by way of a loan agreement on January 30, 2020 (the "Heritage Loan"). The Heritage Loan was scheduled to mature on January 30, 2022 but was repaid prior to maturity. Trichome received repayment of the entire outstanding principal balance, as well as all accrued interest, commitment fees and any other payment obligations (including legal fees and expenses) owing up to the date of repayment (less amortization payments already received), which resulted in net proceeds of \$4,725,789.53.**
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
- On March 18, 2021, the Issuer closed the Trichome Transaction. The Trichome Transaction, which was previously announced on December 30, 2020, was completed pursuant to a plan of arrangement under the *Business Corporations Act* (Ontario).**
-

The Trichome Transaction was implemented pursuant to the terms and conditions of an arrangement agreement dated December 30, 2020, as amended, which resulted in the Issuer's acquisition of all of the issued and outstanding shares of Trichome (the "Trichome Shares").

Pursuant to the terms of the Trichome Transaction, former holders of Trichome Shares and former holders of Trichome convertible instruments (the "Trichome Securityholders") received 0.24525 of a Common Share for each Trichome Share held and each in-the-money convertible instrument of Trichome. As a result of the Trichome Transaction, a total of 10,104,901 Common Shares were issued to the Trichome Securityholders, resulting in former Trichome Securityholders holding approximately 20.06% of the total number of issued and outstanding Common Shares immediately after closing. In addition, 100,916 Common Shares were issued to financial advisors for advisory fees in connection with the Trichome Transaction.

Trichome was not a Related Person to the Issuer and was acquired at arm's length. Prior to the Trichome Transaction, the Issuer did not hold any Trichome Shares.

8. Describe the acquisition of new customers or loss of customers.

- On March 30, 2021, Adjupharm and Zur Rose reached a settlement to terminate their medical cannabis sales agreement that was announced by the Issuer on July 15, 2020.
- During March 2021, Adjupharm entered into the Reseller Agreements to provide the Resellers with COVID-19 rapid antigen tests, as further described under Section 5.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Issuer acquired intangible assets and goodwill as part of the Trichome Transaction (see Section 7). These assets will be capitalized on the Issuer's balance sheet. None of the acquired intangible assets are considered material with the exception of pending intellectual property registrations related to the "Wagners" brand, which Trichome had applied for prior to the closing of the Trichome Transaction. The exact value of the acquired intangible assets are not yet known as Management is currently finalizing post-closing purchase price allocations with respect to the Trichome Transaction.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	56,330	Exercise of incentive stock options.	\$231,603 to be used for working capital
	31,369	Exercise of warrants.	\$163,118.8 to be used for working capital
	10,104,901	Issued to Trichome Securityholders as consideration for the Trichome Transaction, as further detailed in Section 7.	Not Applicable
	100,916	Issued to financial advisors for advisory fees in connection with the Trichome Transaction, as further detailed in Section 7.	Not Applicable
Incentive Stock Options	700,000	Each incentive stock option granted on March 18, 2021 is exercisable for one common share at an exercise price of \$10.02 for a period of five years from the grant date.	Not Applicable

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

- **On March 12, 2021, the Issuer provided Trichome with a \$500,000 loan, evidenced by way of a promissory note issued by Trichome to the Issuer (the "Promissory Note"). The Promissory Note carried an interest rate of 5% and was secured against loan receivables owing to Trichome from certain debtors of Trichome. This loan was repaid by Trichome on April 1st, 2021.**
- **In March 2021, I.M.C. Holdings Ltd. provided Adjupharm with a €3,500,000 loan as a drawdown (the "Drawdown") under a pre-existing credit agreement dated April 26, 2019. The Drawdown carries an interest rate of 4% per annum and is to be repaid within 2 years.**

16. Provide details of any changes in directors, officers or committee members.

Not Applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The current global uncertainty with respect to the spread of COVID-19, the rapidly evolving nature of the pandemic and local and international developments related thereto and its effect on the broader global economy and capital markets may impact the Issuer's business in the coming months.

The Issuer has taken proactive measures to protect the health and safety of its employees in order to continue delivering high quality medical cannabis products to its patients and to maintain its financial health. The Issuer has postponed planned investments in certain jurisdictions until global economic risks subside, but it continues to focus on its acquisition strategy in North America and Europe. The Issuer also continues to develop the IMC brand by increasing physician awareness and engagement to drive sales of IMC-branded medical cannabis products in Germany and by seeking new supply and sales agreements in Israel.

While the precise impact of the COVID-19 outbreak on the Issuer remains unknown, the rapid spread of COVID-19 and declaration of the outbreak as a global pandemic have resulted in travel advisories and restrictions, certain restrictions on business operations, social distancing precautions and restrictions on group gatherings which could have negative impact on businesses around the world, including the cannabis markets in which the Issuer and its subsidiaries and related companies operate. Such implications may also affect Trichome's debtors, including their respective abilities to repay their obligations. The spread of COVID-19 may also have a material adverse effect on global economic activity and could result in volatility and disruption to global supply chains and the financial and capital markets. These disruptions could cause interruptions in supplies and other services from third parties upon which the Issuer relies; decrease demand for products; and cause staff shortages, reduced customer traffic, and increased government regulation, all of which may materially and negatively impact the business, financial condition and results of operations of the Issuer, its subsidiaries and Focus Medical.

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 9, 2021

Oren Shuster

Name of Director or Senior Officer

"Oren Shuster"

Signature

Chief Executive Officer

Official Capacity

Issuer Details Name of Issuer IM Cannabis Corp.	For Month End March 2021	Date of Report YY/MM/D 2021/04/09
Issuer Address 550 Burrard Street, Suite 2300, Bentall 5		
City/Province/Postal Code Vancouver, BC V6C 2B5	Issuer Fax No. ()	Issuer Telephone No. +972 546687515
Contact Name Yael Harrosh	Contact Position General Counsel and Business Manager	Contact Telephone No. +972 546687515
Contact Email Address yael.h@imcannabis.com	Web Site Address http://www.imcannabis.com/	



IM Cannabis Provides Update on Adjupharm Business Developments in Germany

IMC Subsidiary, Adjupharm, Signs New Supply Agreement to Expand Product Portfolio

Agreement with Northern Green Canada Strengthens Adjupharm's Position as Leading EU GMP-Certified Medical Cannabis Distributor in Europe

Toronto, Canada; Bad Oldesloe, Germany; and Glil Yam, Israel - April 12, 2021 - IM Cannabis Corp. ("IMC" or the "Company") (CSE: IMCC, NASDAQ: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Canada, Israel and Germany, today provided a corporate update on its operations in Germany, including the expansion of its product portfolio following the signing of a new supply agreement.

IMC's German-based subsidiary and EU GMP-certified medical cannabis distributor, Adjupharm GmbH ("Adjupharm"), serves as the Company's distribution hub for EU expansion. It has binding sales agreements with distributions partners, reaching over 6,000 pharmacies. Adjupharm recently signed a supply agreement with Northern Green Canada ("NGC") to provide Adjupharm with EU GMP-certified medical cannabis.

"As a patient-first company and trusted partner of the global medical community, IMC is laser-focused on partnering with the best-in-class producers of the highest-quality medical cannabis strains to satisfy the requirements of our German patients," said Oren Shuster, CEO of IMC. "As a leading global operator, IMC sets the standard for providing exceptional cannabis products. The deep knowledge of the medical cannabis industry that we've gained over the past 10 years allows us to adhere to the highest standards."

Headquartered in Ontario, Canada, NGC is the first privately owned Canadian-licensed cannabis producer to achieve EU GMP certification and currently operates a 2,500 square-meter indoor growing and processing facility.

"Our strategic agreement with NGC supports Adjupharm's momentum and mission," added Richard Balla, CEO of Adjupharm. "Our first priority has always been to address the growing demand from both patients and physicians for the best medical cannabis available. As Adjupharm strives to meet these increasing demands, the supply agreement with NGC allows us to strengthen our distribution network and grow our product portfolio, positioning us to remain ahead of the curve."

IMC also announced today that the Company and Zur Rose Pharma GmbH have reached a settlement to terminate the purchase agreement announced on July 15, 2020, effective on March 30, 2021.

About IM Cannabis Corp.

IMC is an MCO in the medical and adult-use recreational cannabis sector, headquartered in Israel and with operations in Israel, Germany and Canada. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry.

In Europe, IMC operates through Adjupharm, a German-based subsidiary and EU GMP-certified medical cannabis distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.

In Canada, IMC operates through Trichome JWC Acquisition Corp. d/b/a JWC. JWC is a licensed producer located in Kitchener, Ontario, selling cannabis flower, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and Wagners brands. JWC operates with the highest standards for providing clean, consistent, aeroponically-grown premium cannabis products to medical patients and the adult-use market throughout Canada and the world. On March 31st, IMC entered into a definitive agreement to acquire MYM Nutraceuticals Inc. ("MYM") and its licensed producer subsidiary, Highland Grow Inc. This transaction, once completed, will reinforce IMC's goal of being a leading global premium cannabis producer and purveyor.

About Northern Green Canada Inc.

NGC is a federally licensed, EU GMP-certified producer of medical cannabis, focused on providing cannabis medications for a better quality of life. NGC is a research and development driven company committed to the health and well-being of patients. Their experienced team of experts operates in an EU GMP-certified, 2500 m² (27000 square foot) indoor growing and processing facility with a 4275 m² (46000 square foot) expansion capability. The company is expanding their extraction capacity to produce oils and working with respected partners on treatment-based cannabis medications. Find more information on their website www.northerngreencanada.com

Disclaimer for Forward-Looking Statements

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "**forward-looking information**"). Forward-looking information are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to the supply agreements providing Adjupharm with EU GMP-certified medical cannabis, the Company entering into future supply agreements, the Company being able to increase its product portfolio, completion of the acquisition of MYM and the Company's business and strategic plans.

Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to the ability of the Company to execute its business plan, the continued growth of the medical and/or recreational cannabis markets in the countries in which the Company operates or intends to operate, the Company maintaining "de facto" control over Focus Medical Herbs Ltd. ("Focus Medical") in accordance with IFRS 10, Focus Medical maintaining its existing Israeli medical cannabis propagation and cultivation licenses and the expected decriminalization and/or legalization of adult-use recreational cannabis in Israel. The Company considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those expressed or implied in the forward-looking information. Such risks include, without limitation: the ability of IMC to complete the acquisition of MYM pursuant to a plan of arrangement under the *Business Corporations Act* (British Columbia) (the "Transaction") on the terms contemplated by the definitive agreement entered into on April 1, 2021 and including the receipt, in a timely manner, of all the regulatory, court, securityholder, stock exchange and other third-party approvals necessary to consummate the Transaction; the Company's inability to capture the benefits associated with its acquisition of Trichome Financial Inc.; unexpected disruptions to the operations and businesses of the Company and/or Focus Medical as a result of the COVID-19 global pandemic or other disease outbreaks including a resurgence in the cases of COVID-19; the Israeli government deciding to delay or abandon the decriminalization and/or legalization of adult-use recreational cannabis; any bill relating to the decriminalization and/or legalization of adult-use recreational cannabis in Israel being rejected by Israeli parliament; any change in the political environment which would negatively affect the decriminalization and/or legalization of adult-use recreational cannabis in Israel; engaging in activities considered illegal under United States federal law; the ability of the Company to comply with applicable government regulations in a highly regulated industry; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture or use of medical cannabis in Israel, Germany, or any other foreign jurisdictions in which the Company intends to operate; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture or use of adult-use recreational cannabis in Canada; any failure of the Company to maintain "de facto" control over Focus Medical in accordance with IFRS 10; the Company and Focus Medical having to rely on third party cannabis producers to supply the Adjupharm and Focus Medical with product to successfully fulfill previously announced sales agreements and purchase commitments; the ability of Focus Medical and Adjupharm to deliver on their sales commitments; the risk that regulatory authorities in Israel may view the Company as the deemed owner of more than 5% of Focus Medical in contravention to Israeli rules restricting the ownership of Israeli cannabis cultivators and thereby jeopardizing Focus Medical's cannabis propagation or cultivation licenses; any unexpected failure of Focus Medical to renew its propagation or cultivation licenses with the Israeli Ministry of Health; any unexpected failure of Focus Medical to maintain any of its commercial facilities or land lease agreements; any unexpected failure of Adjupharm to renew its production, wholesale, narcotics handling or import/export licenses, permits, certificates or approvals; the Company's reliance on management; the lack of merger and acquisition opportunities; inconsistent public opinion and perception regarding the use of cannabis; perceived effects of medical cannabis products; the Company's ability to maintain or improve the brand position of the IMC brand in Israel's medical cannabis market; political instability and conflict in the Middle East; adverse market conditions; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; costs of inputs; crop failures; litigation; currency fluctuations; competition; industry consolidation; failure to meet NASDAQ's continued listing requirements; and loss of key management and/or employees.

For more information:

Oren Shuster
CEO, IM Cannabis
+972-77-3603504
info@imcannabis.com

Gal Wilder
Media Relations - Canada
+1 416-602-4092
gwilder@cohnwolfe.ca

Caitlin Kasunich
Media Relations
+1 212-896-1241
ckasunich@kcsa.com

Elizabeth Barker
Investor Relations
+1 212-896-1203
ebarker@kcsa.com
